612 related articles for article (PubMed ID: 7729684)
1. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Matsuoka S; Edwards MC; Bai C; Parker S; Zhang P; Baldini A; Harper JW; Elledge SJ
Genes Dev; 1995 Mar; 9(6):650-62. PubMed ID: 7729684
[TBL] [Abstract][Full Text] [Related]
2. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
Lee MH; Reynisdóttir I; Massagué J
Genes Dev; 1995 Mar; 9(6):639-49. PubMed ID: 7729683
[TBL] [Abstract][Full Text] [Related]
3. Pituitary adenylate cyclase activating polypeptide anti-mitogenic signaling in cerebral cortical progenitors is regulated by p57Kip2-dependent CDK2 activity.
Carey RG; Li B; DiCicco-Bloom E
J Neurosci; 2002 Mar; 22(5):1583-91. PubMed ID: 11880488
[TBL] [Abstract][Full Text] [Related]
4. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.
Bourcigaux N; Gaston V; Logié A; Bertagna X; Le Bouc Y; Gicquel C
J Clin Endocrinol Metab; 2000 Jan; 85(1):322-30. PubMed ID: 10634406
[TBL] [Abstract][Full Text] [Related]
5. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.
Luo Y; Hurwitz J; Massagué J
Nature; 1995 May; 375(6527):159-61. PubMed ID: 7753174
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
Orlow I; Iavarone A; Crider-Miller SJ; Bonilla F; Latres E; Lee MH; Gerald WL; Massagué J; Weissman BE; Cordón-Cardó C
Cancer Res; 1996 Mar; 56(6):1219-21. PubMed ID: 8640801
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome.
Bhuiyan ZA; Yatsuki H; Sasaguri T; Joh K; Soejima H; Zhu X; Hatada I; Morisaki H; Morisaki T; Mukai T
Hum Genet; 1999 Mar; 104(3):205-10. PubMed ID: 10323243
[TBL] [Abstract][Full Text] [Related]
8. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain.
Joaquin M; Watson RJ
J Biol Chem; 2003 Nov; 278(45):44255-64. PubMed ID: 12947099
[TBL] [Abstract][Full Text] [Related]
9. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.
Watanabe H; Pan ZQ; Schreiber-Agus N; DePinho RA; Hurwitz J; Xiong Y
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1392-7. PubMed ID: 9465025
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
11. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse.
Hatada I; Mukai T
Nat Genet; 1995 Oct; 11(2):204-6. PubMed ID: 7550351
[TBL] [Abstract][Full Text] [Related]
12. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.
Goubin F; Ducommun B
Oncogene; 1995 Jun; 10(12):2281-7. PubMed ID: 7784076
[TBL] [Abstract][Full Text] [Related]
13. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.
Yan Y; Frisén J; Lee MH; Massagué J; Barbacid M
Genes Dev; 1997 Apr; 11(8):973-83. PubMed ID: 9136926
[TBL] [Abstract][Full Text] [Related]
14. p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts.
Takahashi K; Kobayashi T; Kanayama N
Mol Hum Reprod; 2000 Nov; 6(11):1019-25. PubMed ID: 11044465
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.
Tsihlias J; Zhang W; Bhattacharya N; Flanagan M; Klotz L; Slingerland J
Oncogene; 2000 Feb; 19(5):670-9. PubMed ID: 10698512
[TBL] [Abstract][Full Text] [Related]
16. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Harper JW; Adami GR; Wei N; Keyomarsi K; Elledge SJ
Cell; 1993 Nov; 75(4):805-16. PubMed ID: 8242751
[TBL] [Abstract][Full Text] [Related]
17. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages.
Matsuoka M; Tani K; Asano S
Oncogene; 1998 Apr; 16(16):2075-86. PubMed ID: 9572488
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivo.
Gómez Lahoz E; Liegeois NJ; Zhang P; Engelman JA; Horner J; Silverman A; Burde R; Roussel MF; Sherr CJ; Elledge SJ; DePinho RA
Mol Cell Biol; 1999 Jan; 19(1):353-63. PubMed ID: 9858559
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
